Blue­bird’s star gene ther­a­py pa­tient still do­ing well af­ter 15 months-plus; Take­da, Ar­ix part­ner on biotech star­tups

→ Every biotech en­joys a good suc­cess sto­ry, and blue­bird bio $BLUE got their write­up in the New Eng­land Jour­nal of Med­i­cine. Pa­tient 1204 in blue­bird’s pro­gram for Lenti­Glo­bin gene ther­a­py pro­gram has had more than 15 months of fol­lowup, and his physi­cians say that the teenag­er has been free of the painful symp­toms of sick­le cell dis­ease, able to lead a nor­mal life and stop painful trans­fu­sions. That’s all a pos­i­tive, but blue­bird’s gene ther­a­py has al­so proven to be some­what vari­able among pa­tients. One suc­cess sto­ry does not make for a suc­cess­ful ther­a­py, but it’s still a plus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER